CONTACT
Respiratory diseases

Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands

AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart dsease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug

Read more
1 September 2015

Burden of Exacerbations in Patients with Moderate to Very Severe COPD in the Netherlands: A Real-life Study

OBJECTIVE: The objective of this study was to compare rates of different types of acute exacerbations of COPD (AECOPDs) and healthcare utilization among patients with different severities of COPD. METHODS: Data for this study was obtained from theHARMO Database Network, which includes drug dispensing records from pharmacies, hospitalization records and information from general practitioners

Read more
1 April 2015

Antibiotic prescribing on admission to patients with pneumonia and prior outpatient antibiotic treatment: a cohort study on clinical outcome

OBJECTIVE: Most pneumonia treatment guidelines recommend that prior outpatient antibiotic treatment should be considered when planning inpatient antibiotic regimen. Our purpose was to study in patients admitted for community-acquired pneumonia theode of continuing antibiotic treatment at the outpatient to inpatient transition and the subsequent clinical course

Read more
1 January 2015

Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study

BACKGROUND: We aimed to determine whether (1) patients with obstructive pulmonary disease (OPD) have an increased risk of sudden cardiac arrest (SCA) due to ventricular tachycardia or fibrillation (VT/VF), and (2) the SCA risk is mediated by cardioascular risk-profile and/or respiratory drug use. METHODS: A community-based case-control study was performed, with 1310 cases of SCA of the ARREST study and 5793 age, sex and SCA-date matched non-SCA controls from the PHARMO database

Read more
1 January 2013

Which long-acting bronchodilator is most cost-effective for the treatment of COPD?

Background: The aim of this study was to estimate the cost-effectiveness of tiotropium versus salmeterol to inform decision making within the Dutch healthcare setting. Methods: A previously published, validated COPD progression model was updated wih new exacerbation data and adapted to the Dutch setting by including Dutch estimates of healthcare use for COPD maintenance treatment and Dutch unit costs

Read more
1 October 2012

Evaluation of smoking cessation drug use and outcomes in the Netherlands

OBJECTIVE: Several pharmacological therapies are available to help smokers quit. The aim was to investigate the utilisation and effectiveness of smoking cessation drugs in daily practice in the Netherlands. METHODS: Subjects aged >/=18 years with apharmacy prescription of varenicline, bupropion, nicotine replacement therapy (NRT) or nortriptyline between March 2007 and September 2008 were identified from the PHARMO data warehouse, which includes drug dispensing, hospitalisation and other data fromapproximately 2

Read more
1 January 2011

Measuring exacerbations in obstructive lung disease

PURPOSE: Using hospitalization always has been seen as a solid measurement for exacerbation in pharmacoepidemiology, but might lead to an underestimation of disease exacerbation because of a trend towards outpatient care. The aim of this study waso quantify the incidence of different exacerbation markers in obstructive lung disease and to identify predictors for these exacerbation markers

Read more
1 April 2010

Medication changes prior to hospitalization for obstructive lung disease: a case-crossover study

BACKGROUND: Hospitalizations have always been seen as a solid outcome parameter in pharmacoepidemiology. However, the period leading to hospitalization and prehospital management of the patient are equally important. OBJECTIVE: To evaluate medicatin changes in the period prior to hospitalization for obstructive lung disease and to quantify the association between medication use and the risk of hospitalization

Read more
1 February 2010

Effects of corticosteroid use on readmission in obstructive lung disease

OBJECTIVE: Obstructive lung disease is a leading cause of morbidity and mortality worldwide. Some patients are readmitted, but currently predicting parameters for identifying these patients are lacking. The aim of this study was to quantify the incdence of readmission in chronic obstructive lung disease and to identify determinants for hospital readmission

Read more
1 February 2010

Filter by

Therapeutic area’s

Type of study